Cholecystitis News and Research

RSS

Orexigen Therapeutics announces new data from COR-I, COR-II and COR-Diabetes trials for Contrave

Orexigen® ( )Therapeutics, Inc today announced new data from the COR-I, COR-II and COR-Diabetes trials for Contrave® (bupropion SR/ naltrexone SR) to expand on top-line results announced in July. Contrave is the first of the Company's two late stage candidates for the treatment of obesity.

26 Oct 2009

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.

26 Aug 2009

Gallbladder emptying in primary sclerosing cholangitis patients

Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic inflammatory liver disease characterized by diffuse fibrosing inflammation of intra- and/or extrahepatic bile ducts, resulting in bile duct obliteration, biliary cirrhosis, and eventually hepatic failure. One of the most common symptoms at the time of presentation of PSC is mild to severe abdominal pain localized in the right upper quadrant. However, the mechanisms responsible for the abdominal pain in PSC are not fully understood.

10 Aug 2009

Nanobac announces Baylor initial results for nanoparticle and gall stone formation study

Nanobac Pharmaceuticals Inc has announced that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones).

15 Jan 2008

Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases

A retrospective case-control study of 21,008 women in Finland has found that those with intrahepatic cholestasis of pregnancy (ICP), an itchy skin condition when bile gets backed up in the liver, are significantly more likely to suffer other liver diseases later in life.

7 Apr 2006

Wide variation in the use of laparoscopic surgery for gall bladder removal

There is a wide variation in the use of laparoscopic surgery for gall bladder removal in Hong Kong hospitals, and use of this procedure is more likely at certain hospitals and among younger female patients operated on more recently, according to a study in the Archives of Surgery.

7 Dec 2005

Estrogen therapy may increase risk for gallbladder disease

Dominic J. Cirillo, B.S., of the University of Iowa, Iowa City, and colleagues examined data from the Women’s Health Initiative (WHI), which were two randomized, double-blind, placebo-controlled trials conducted at 40 U.S. clinical centers.

19 Jan 2005

FDA updates Zelnorm labeling a treatment of women with irritable bowel syndrome

The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.

30 Apr 2004